Skip to main content
SpringerLink
Log in

Targeted Therapy: Vascular Endothelial Growth Factor

  • Chapter
  • First Online:
Renal Cell Carcinoma

Part of the book series: Current Clinical Urology ((CCU))

  • 1877 Accesses

Abstract

In recent years the therapeutic approach to metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction of new and effective vascular endothelial growth factor (VEGF)-targeted therapies. The current guidelines suggest Sunitinib, Bevacizumab plus IFNa or Pazopanib as first-line treatments for favorable and intermediate-risk patients with mRCC. Sorafenib, Sunitinib, Pazopanib, and Axitinib can be recommended as second-line treatments for cytokine refractory mRCC. The correct management of side effects is a crucial point to permit more efficacious treatment. Research is now focused on identifying prognostic and predictive factors; clinical, biological, and genetic algorithms to create a treatment that would allow patients the best and personalized therapeutic approach, taking comorbidities into account. Current trials are investigating the best way to overcome drug resistance via sequential or combination approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028–43.

    Article  PubMed  CAS  Google Scholar 

  2. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.

    Article  PubMed  Google Scholar 

  3. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

    Article  PubMed  CAS  Google Scholar 

  5. Motzer RJ, Redman BG, Rini BI, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.

    Article  PubMed  CAS  Google Scholar 

  6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  PubMed  CAS  Google Scholar 

  7. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.

    Article  PubMed  CAS  Google Scholar 

  8. Sternberg CN. ESMO. Ann Oncol. 2010;LBA:22.

    Google Scholar 

  9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.

    Article  Google Scholar 

  10. Szczylik C, Bukowski RM, Escudier B, et al. Randomized phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25 [Abstr 5025].

    Google Scholar 

  11. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8:975–84.

    Article  PubMed  Google Scholar 

  12. Rini BI, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol. 2011; 29 [Abstr 4504].

    Google Scholar 

  13. Rini BI, et al. Diastolic blood pressure as a biomarkert of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841–9.

    Article  PubMed  CAS  Google Scholar 

  14. Jonasch E, Bair A, Rini BI, et al. Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2010;28 [Abstr TPS235].

    Google Scholar 

  15. Nosov D, Bhargava P, Esteves WB, et al. Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). J Clin Oncol. 2011; 29 [Abstr 4550].

    Google Scholar 

  16. Motzer RJ, Sternberg CN, Hutson TE, et al. A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 2011; 29 [Abstr 310].

    Google Scholar 

  17. Angevin E, Grünwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol. 2011; 29 [Abst 4551].

    Google Scholar 

  18. Casanovas O, Hicklin D, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299–309.

    Article  PubMed  CAS  Google Scholar 

  19. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol. 2008; 26 [Abstr 5047].

    Google Scholar 

  20. Mulders P, Hawkins R, Nathan P, et al. Final results of a phase II randomised study of cediranib (RECENTINTM) in patients with advanced renal cell carcinoma (RCC). EJC Suppl. 2009;7:21.

    Google Scholar 

  21. Roodjart JM, Langeberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharm. 2008;3:132–43.

    Article  Google Scholar 

  22. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010;36:416–24.

    Article  PubMed  CAS  Google Scholar 

  23. Di Lorenzo G, Porta C, Sternberg C, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59:526–40.

    Article  PubMed  Google Scholar 

  24. Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084–96.

    Article  PubMed  CAS  Google Scholar 

  25. Bhojani N, Jeldres C, Patard J-J, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917–30.

    Article  PubMed  CAS  Google Scholar 

  26. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81–3.

    Article  PubMed  CAS  Google Scholar 

  27. Wolter P, Dumez H, Schöffski P. Sunitinib and hypothyroidism. N Engl J Med. 2007;356:1580–1.

    Article  PubMed  CAS  Google Scholar 

  28. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99:448–54.

    Article  PubMed  CAS  Google Scholar 

  29. Iglesias P, Diez JJ. Thyroid function and kidney disease. Eur J Endocrinol. 2009;160:503–15.

    Article  PubMed  CAS  Google Scholar 

  30. Langenberg MHG, Van Herpen CML, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152–9.

    Article  PubMed  CAS  Google Scholar 

  31. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9–17.

    Article  PubMed  CAS  Google Scholar 

  32. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807–15.

    Article  PubMed  CAS  Google Scholar 

  33. Vaklavas C, Lenihan D, Kurzrock R, et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical marker to target? Oncologist. 2010;15:130–41.

    Article  PubMed  CAS  Google Scholar 

  34. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–12.

    Article  PubMed  Google Scholar 

  35. Lenihan DJ. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol. 2008;26:5154–5.

    Article  PubMed  Google Scholar 

  36. Bamias A, Lainakis G, Manios E, et al. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol. 2009;27:2567–9.

    Article  PubMed  Google Scholar 

  37. Chu D, Lacouture ME, Weiner E, et al. Risk of hand–foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11–9.

    Article  PubMed  Google Scholar 

  38. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001–11.

    Article  PubMed  CAS  Google Scholar 

  39. Dasanu CA, Dutcher J, Alexandrescu DT. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100(3):328–30.

    Article  PubMed  Google Scholar 

  40. Izzedine H, Massard C, Spano JP, et al. VEGF signaling inhibition-induced proteinuria: mechanism, significance and management. Eur J Cancer. 2010;46:439–48.

    Article  PubMed  CAS  Google Scholar 

  41. Rini BI, Jaegert E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metatstatic renal cell carcinoma: impact of patient characteristics and Von Hippel–Lindau gene status. BJU. 2007;98:756–62.

    Google Scholar 

  42. Xu CF, Bing NX, Sternberg CN, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011;29(18):2557–64.

    Article  PubMed  CAS  Google Scholar 

  43. Johannsen M, Flörcken A, Bex A, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009;55:1430–9.

    Article  PubMed  CAS  Google Scholar 

  44. Grépin R, Pagès G. Molecular mechanism of resistance to tumour anti-angiogenic strategies. J Oncol. 2010;1–8.

    Google Scholar 

  45. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432–9.

    Article  PubMed  CAS  Google Scholar 

  46. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res. 2007;13:5232–7.

    Article  PubMed  CAS  Google Scholar 

  47. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007;13:764s–9.

    Article  PubMed  CAS  Google Scholar 

  48. Hutson TE, Bukowski RM, Sternberg CN, et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011;77:48–62.

    Article  PubMed  Google Scholar 

  49. Eichelberg C, Heuer R, Chun FK, et al. Sequential use of tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008;54:1373–8.

    Article  PubMed  CAS  Google Scholar 

  50. Bracarda S, Bellmunt J, Ravaud A, et al. Overall serviva in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2010;107:214–9.

    Article  PubMed  Google Scholar 

  51. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009;27:3225–34.

    Article  PubMed  CAS  Google Scholar 

  52. Escudier B, Albiges L, Blesius A, et al. How to select targeted therapy in renal cell cancer. Ann Oncol. 2010;21:vii59–62.

    Article  PubMed  Google Scholar 

  53. Bellmunt J, Flodgren P, Roigas J, et al. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int. 2009;104:10–8.

    Article  PubMed  CAS  Google Scholar 

  54. Heng DYC, Xie W, Bjarnason GA, et al. Progression free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2010;117(12):2637–42.

    Article  PubMed  Google Scholar 

  55. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, San Camillo-Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, 00152, Italy

    Linda Cerbone & Cora N. Sternberg

Authors
  1. Linda Cerbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cora N. Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cora N. Sternberg .

Editor information

Editors and Affiliations

  1. Glickman Urological and Kidney Institute, Center for Urologic Oncology, Cleveland Clinic, Cleveland, 44195, Ohio, USA

    Steven C. Campbell

  2. College of Medicine, Case Western Reserve University, Cleveland Clinic Lerner, Department of Solid Tumor Oncology, Cleveland, 44195, Ohio, USA

    Brian I. Rini

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cerbone, L., Sternberg, C.N. (2013). Targeted Therapy: Vascular Endothelial Growth Factor. In: Campbell, S., Rini, B. (eds) Renal Cell Carcinoma. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-062-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-062-5_17

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-061-8

  • Online ISBN: 978-1-62703-062-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation